Literature DB >> 12114787

Angiogenesis in Endocrine Neoplasms.

Martin Jugenburg1, Kalman Kovacs, Ivan Jugenburg, Bernd W. Scheithauer.   

Abstract

Angiogenesis promotes the growth of tumors, because it both facilitates oxygenation and nutrient flow, and removes metabolic waste. During the past two decades, as the importance of tumor vascularity became recognized, angiogenesis and the relationship between blood vessels and tumor progression received increasing attention. It was found that isolated tumor tissues failed to expand beyond few millimeters unless vascularized, whereupon vascularization they exhibited a rapid growth. Extensive research focusing on the relationship between tumor proliferation and the formation of new vessels has initially been undertaken to assess the role of angiogenesis in the progression of breast carcinomas. Significant results emerged from these investigations, and similar studies were extended to other tumor types, such as melanomas, cervical and pulmonary carcinomas, and so on. It is of note that angiogenesis as it relates to endocrine tumors has so far been limited to pituitary neoplasms, thyroid carcinomas, and pheochromocytomas. The purpose of the article is to provide a brief review of angiogenesis and to summarize available data regarding its role in the growth off endocrine neoplasms.

Entities:  

Year:  1997        PMID: 12114787     DOI: 10.1007/BF02739928

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  97 in total

1.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

2.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.

Authors:  B Millauer; L K Shawver; K H Plate; W Risau; A Ullrich
Journal:  Nature       Date:  1994-02-10       Impact factor: 49.962

4.  Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.

Authors:  K Samoto; K Ikezaki; M Ono; T Shono; K Kohno; M Kuwano; M Fukui
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

5.  Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice.

Authors:  A J Pötgens; N H Lubsen; M C van Altena; J G Schoenmakers; D J Ruiter; R M de Waal
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

6.  Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro.

Authors:  Y Sato; K Okamura; A Morimoto; R Hamanaka; K Hamaguchi; T Shimada; M Ono; K Kohno; T Sakata; M Kuwano
Journal:  Exp Cell Res       Date:  1993-02       Impact factor: 3.905

7.  Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland.

Authors:  M M Esiri; J S Bevan; C W Burke; C B Adams
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

8.  T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas.

Authors:  G Herrmann; P M Schumm-Draeger; C Müller; E Atai; B Wenzel; T Fabian; K H Usadel; K Hübner
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck.

Authors:  D Albo; M S Granick; N Jhala; B Atkinson; M P Solomon
Journal:  Ann Plast Surg       Date:  1994-06       Impact factor: 1.539

Review 10.  Tumour vasculature--a potential therapeutic target.

Authors:  C T Baillie; M C Winslet; N J Bradley
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more
  2 in total

1.  Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.

Authors:  Slawomir A Mucha; Gabriela Meleń-Mucha; Andrzej Godlewski; Henryk Stepień
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

2.  Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.

Authors:  Lucia Stefaneanu; Kalman Kovacs; Bernd W. Scheithauer; George Kontogeorgos; Darren L. Riehle; Thomas J. Sebo; David Murray; Sergio Vidal; Ami Tran; Michael Buchfelder; Rudolf Fahlbusch
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.